$CC

UBS Adjusts Chemours Price Target to $16 From $18, Maintains Neutral Rating

UBS reduced its price target for Chemours from $18 to $16 while maintaining a neutral rating. The stock is currently trading at $13.49, down 1.60% on the day and 4.32% over the past year, but up 14.67% over 5 days. The adjustment reflects changes in valuation and earnings revisions.

Original reporting
Published Oct 5, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CC
Bearish
high confidence
Mentioned
$CC
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$CCBearishMed
01

Why it matters

The downgrade may trigger short‑term sell pressure and affect sector sentiment.

02

Market read

Analyst target adjustment provides a fresh trading signal for Chemours (CC).

03

What to watch

Potential cost‑saving initiatives not reflected in the target.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

UBS analyst revised valuation assumptions for Chemours, reducing the price target by $2.

Company-level read

Ticker impact

$CCBearishHigh confidence
Context

UBS lowered Chemours' price target to $16 from $18, indicating a fresh downgrade.

Expected impact

likely pressure as the market prices in the lower valuation.

Evidence & confidence

Analyst target reduction is a new actionable signal for traders.

Market effects

May weigh on other specialty chemicals peers.

Limited to US chemical sector.

Low global impact.

Counterpoint

Target cut could be overly pessimistic if Chemours' fundamentals improve.

Key entities

  • Chemours Company

    US‑listed specialty chemicals producer.

  • UBS

    Equity research firm issuing the target change.

Related articles

$CCHigh

Why is Chemours stock sliding today?

Chemours (CC) stock fell 2.3% in pre-market trading after Mizuho downgraded it to Neutral and cut its price target to $15. RBC also downgraded it to Sector Perform, reducing its target to $14. Both analysts cited concerns over slower earnings growth and weak demand in key markets. The stock has lost over 40% in six months, trading near its 52-week low.

$CCMed

Mizuho downgrades Chemours stock rating on refrigerants delay

Mizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.

$CCHigh

Chemours falls as RBC downgrades stock on persistent TiO2 weakness

Chemours Co (CC) shares dropped 2.5% premarket after RBC downgraded it to Sector Perform, citing weak TiO2 demand and reduced growth expectations. RBC cut its price target to $14 from $22 and lowered EBITDA estimates for Q3 and FY26-FY27, citing macro pressures and project delays. The analyst sees limited near-term upside and a fully valued stock at current levels.

$CCMedAI 8/10

Corporations Are Dodging Accountability for PFAS Contamination Around the Globe

Chemours, a chemical company, has been linked to PFAS contamination in the Cape Fear River, North Carolina, affecting drinking water and health. The state reached a $590M settlement with Chemours for damages. PFAS contamination has also been reported near Chemours' facilities worldwide, raising concerns about global environmental and health impacts. Chemours inherited cleanup liabilities from its former parent company, DuPont, after a 2015 spin-off.